The purpose of this resource is to provide tissue, cells and pathology services to all 4 research projects and to career or research development awardees covered by this application. To achieve these goals, we have integrated pathology resources from the Dan L Duncan Cancer Center at Baylor College of Medicine (BCM) and its affiliated institutions, with those from The Methodist Hospital. This integration both ensures adequate sample numbers and the timely delivery of tissue/cell samples for the needs of project investigators. The core acquires tissues for banking from lymphoma and CLL patients at affiliated hospitals in the Texas Medical Center, exploiting tissue collection and distribution systems that are already in place and that meet TCGA guidelines. Over the past 4 years, the core has successfully provided fresh cells and tissue, FFPE tissue, DNA, and RNA, tissue microarrays, marrow and serum to SPORE and external investigators. The core also provides pathology services, including routine tissue preparation, immunohistochemical staining, laser capture microdissection, preparation of tissue microarrays, flow cytometry, detection of minimal residual disease and in situ hybridization for viral RNAs. In addition, the core contains a cancer genetics laboratory for specialized molecular studies, including FISH and sequencing. These resources are provided by expert pathologists, histotechnologists and molecular biologists with substantial experience in providing core services to SPORE investigators. Finally, the bioinformatics group has expertise in working with the BCM Breast SPOREs to utilize CaTissue resources and has developed both bioinformatics and tissue-banking software needs for the lymphoma SPORE.

Public Health Relevance

The Biospecimen and Pathology Core coljects biospecimens needed by all investigators in this SPORE as well as for other investigators performing lymphoma research for their translational research projects. It provides pathology services to investigators and supports the clinical trials

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Iwahori, Kota; Kakarla, Sunitha; Velasquez, Mireya P et al. (2015) Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 23:171-8
Ngo, Minhtran Charlotte; Ando, Jun; Leen, Ann M et al. (2014) Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 37:193-203
Ok, Chi Young; Li, Ling; Xu-Monette, Zijun Y et al. (2014) Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res 20:2338-49
Bollard, Catherine M; Gottschalk, Stephen; Torrano, Vicky et al. (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32:798-808
Rouce, Rayne H; Louis, Chrystal U; Heslop, Helen E (2014) Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 21:476-81
Leen, Ann M; Heslop, Helen E; Brenner, Malcolm K (2014) Antiviral T-cell therapy. Immunol Rev 258:12-29
Xu, Xin; Hegazy, Wael A H; Guo, Linjie et al. (2014) Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system. Cancer Res 74:6260-70
Zhou, Xiaoou; Di Stasi, Antonio; Tey, Siok-Keen et al. (2014) Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123:3895-905
Papadopoulou, Anastasia; Krance, Robert A; Allen, Carl E et al. (2014) Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther 22:1134-8
Anurathapan, Usanarat; Leen, Ann M; Brenner, Malcolm K et al. (2014) Engineered T cells for cancer treatment. Cytotherapy 16:713-33

Showing the most recent 10 out of 121 publications